NDAORALTABLETPriority Review
Approved
Jun 2007
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Endothelin Receptor Antagonists
Pharmacologic Class:
Endothelin Receptor Antagonist
Clinical Trials (5)
Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants
Started Sep 2019
29 enrolled
Hypertension, Pulmonary
Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension
Started Oct 2017
0Portopulmonary HypertensionPulmonary HypertensionCirrhosis, Liver
Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
Started Oct 2017
0Pulmonary Arterial Hypertension
A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects
Started Mar 2016
112 enrolled
Hypertension, Pulmonary
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
Started Sep 2015
2 enrolled
Pulmonary Arterial Hypertension
Loss of Exclusivity
LOE Date
Oct 14, 2031
68 months away
Patent Expiry
Oct 14, 2031